Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1076-1084

  Kempuraj, D ^a   Tagen, M ^a   Iliopoulou, B P ^a   Clemons, A ^a   Vasiadi, M ^a   Boucher, W ^a   House, M ^a   Wolfberg, A ^a   Theoharides, T C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell activation; Cell cell contact; Cytokines; Inflammation; Jurkat cells; Mast cells; Multiple sclerosis; Myelin basic protein; T cells; TNF

Indexed keywords

AUTACOID; CD3 ANTIBODY; HISTAMINE; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LUTEOLIN; MONOCLONAL ANTIBODY CD28; MYELIN BASIC PROTEIN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALLERGY; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL INTERACTION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME RELEASE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAST CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ASSAY; SUPERNATANT; T LYMPHOCYTE ACTIVATION;

CELLS, CULTURED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-2; JURKAT CELLS; LUTEOLIN; MAST CELLS; MYELIN BASIC PROTEINS; TRYPTASES;

EID: 56749169211     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.356     Document Type: Article

References (61)

1. Bartosik-Psujek H, Belniak E, Mitosek-Szewcryk K, Dobosz B, Stelmasiak Z (2004). Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 109: 390-392.
2. Benoist C, Mathis D (2002). Mast cells in autoimmune disease. Nature 420: 875-878.
3. Bongioanni P, Lombardo F, Moscato G, Mosti S, Meucci G (2000a). T-cell interleukin-6 receptor binding in interferon-b-1b-treated multiple sclerosis patients. Eur J Neurol 7: 647-653.
4. Bongioanni P, Mosti S, Romano MR, Lombardo F, Moscato G, Meucci G (2000b). Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis. Eur J Neurol 7: 291-297.
5. Brill A, Baram D, Sela U, Salamon P, Mekori YA, Hershkoviz R (2004). Induction of mast cell interactions with blood vessel wall components by direct contact with intact T cells or T cell membranes in vitro. Clin Exp Allergy 34: 1725-1731.
6. Brown MA, Tanzola M, Robbie-Ryan M (2002). Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol 38: 1373-1378.
7. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL et al. (2005). Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174: 7665-7675.
8. Carvalho JF, Blank M, Shoenfeld Y (2007). Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 27: 246-256.
9. De Groot CJ, Montagne L, Barten AD, Sminia P, Van der Valk P (1999). Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type 1 and II receptors in multiple sclerosis lesions and human adult astrocyte cultures. J Neuropathol Exp Neurol 58: 174-187.
10. Dietsch GN, Hinrichs DJ (1991). Mast cell proteases liberate stable encephalitogenic fragments from intact myelin. Cell Immunol 135: 541-548.
11. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R et al. (2002). Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 303: 1061-1066.
12. Esposito P, Gheorghe D, Kandere K, Pang X, Conally R, Jacobson S et al. (2001). Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 888: 117-127.
13. Fox RJ, Ransohoff RM (2004). New directions in MS therapeutics: vehicles of hope. Trends Immunol 25: 632-636.
14. Frohman EM, Racke M, Raine CS (2006). Multiple sclerosis - the plaque and its pathogenesis. N Eng J Med 354: 942-955.
15. Galli SJ, Nakae S, Tsai M (2005). Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135-142.
16. Gregory GD, Raju SS, Winandy S, Brown MA (2006). Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. J Clin Invest 116: 1327-1336.
17. Gregory GD, Robbie-Ryan M, Secor VH, Sabatino Jr JJ, Brown MA (2005). Mast cells are required for optimal autoreactive T cell responses in a murine model of multiple sclerosis. Eur J Immunol 35: 3478-3486.
18. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE (2004). Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 200: 1667-1672.
19. Ibrahim MZ, Reder AT, Lawand R, Takash W, Sallouh-Khatib S (1996). The mast cells of the multiple sclerosis brain. J Neuroimmunol 70: 131-138.
20. 2 can stimulate mast cell degranulation. Brain Res 444: 195-198.
21. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W et al. (2003). IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 171: 4830-4836.
22. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N et al. (2005). Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 145: 934-944.
23. Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H et al. (1999). Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93: 3338-3346.
24. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H (2000). Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 30: 501-508.
25. Krüger PG (2001). Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol Appl Neurobiol 27: 275-280.
26. Kumazawa Y, Kawaguchi K, Takimoto H (2006). Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr Pharm Des 12: 4271-4279.
27. Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC (2003). Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. J Neuroimmunol 145: 18-26.
28. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H et al. (2002). Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8: 500-508.
29. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C et al. (2000). Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 177: 95-103.
30. Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S et al. (2004). Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 155: 161-171.
31. Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A et al. (2003). Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis. J Neuroimmunol 138: 115-122.
32. Mekori YA, Metcalfe DD (2000). Mast cells in innate immunity. Immunol Rev 173: 131-140.
33. Middleton Jr E, Kandaswami C, Theoharides TC (2000). The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 52: 673-751.
34. Minagar A, Alexander JS (2003). Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9: 540-549.
35. Mirowska-Guzel DM, Kurowska K, Skierski J, Koronkiewicz M, Wicha W, Kruszewski J et al. (2006). High dose of intravenously given glucocorticoids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. J Neuroimmunol 176: 134-140.
36. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A et al. (1997). Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272: 4043-4049.
37. Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR (1996). Enhanced expression of chemotactic receptors in multiple sclerosis. J Neurol Sci 144: 135-141.
38. Nakae S, Suto H, Berry GJ, Galli SJ (2007). Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 109: 3640-3648.
39. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M et al. (2006). Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176: 2238-2248.
40. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ (2005). Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA 102: 6467-6472.
41. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000). Multiple sclerosis. N Eng J Med 343: 938-952.
42. Ohta M, Ohta K (2002). Detection of myelin basic protein in cerebrospinal fluid. Expert Rev Mol Diagn 2: 627-633.
43. Pedotti R, De Voss JJ, Steinman L, Galli SJ (2003). Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 24: 479-484.
44. Prescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merill MJ (2002). Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61: 914-925.
45. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC (1995). Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37: 63-66.
46. Ruuls SR, Bauer J, Sontrop K, Huitinga I, 't Hart BA, Dijkstra CD (1995). Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56: 207-217.
47. Sadik CD, Sies H, Schewe T (2003). Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action. Biochem Pharmacol 65: 773-781.
48. Salamon P, Shoham NG, Gavrieli R, Wolach B, Mekori YA (2005). Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 60: 1316-1319.
49. Sellebjerg F, Christiansen M, Nielsen PM, Frederiksen JL (1998). Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler 4: 475-479.
50. Silver R, Silverman A-J, Vitkovic L, Lederhendler II (1996). Mast cells in the brain: evidence and functional significance. Trends Neurosci 19: 25-31.
51. Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA et al. (1995). Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 45: 1122-1126.
52. Su JJ, Osoegawa M, Matsuoka T, Minohara M, Tanaka M, Ishizu T et al. (2006). Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243: 21-30.
53. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM et al. (1993). Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 151: 4637-4641.
54. Theoharides TC (1990). Mast cells: the immune gate to the brain. Life Sci 46: 607-617.
55. Theoharides TC, Dimitriadou V, Letourneau RJ, Rozniecki JJ, Vliagoftis H, Boucher WS (1993). Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. Neuroscience 57: 861-871.
56. Theoharides TC, Kalogeromitros D (2006). The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 1088: 78-99.
57. Theoharides TC, Konstantinidou A (2007). Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 12: 1615-1628.
58. Tuomisto L, Kilpelainen H, Riekkinen P (1983). Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis. Agents Action 13: 255-257.
59. Verbeek R, Plomp AC, van Tol EA, van Noort JM (2004). The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. Biochem Pharmacol 68: 621-629.
60. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006). Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
61. Zappulla JP, Arock M, Mars LT, Liblau RS (2002). Mast cells: new targets for multiple sclerosis therapy? J Neuroimmunol 131: 5-20.